Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11376263
Cyproterone acetate compositions and uses thereof
granted -
US 11377444
Pyridopyrimidine compounds acting as mTORC 1/2 dual inhibitors
granted -
US 11377447
Targeted therapeutics
granted -
US 11377451
Compositions and methods for treating cancer
granted -
CA 3203431
PROCEDES D'AMELIORATION DE RENDEMENT MUSCULAIRE OU DE REDUCTION DE FATIGUE CHRONIQUE PAR ADMINISTRATION D'EXOSOMES DERIVES DU LAIT BOVIN
granted -
CA 3203434
PROCEDE D'AMELIORATION DE LA SANTE ARTICULAIRE PAR ADMINISTRATION D'EXOSOMES DERIVES DU LAIT DE VACHE
granted -
US 11385201
Ultra-stable protein ionic liquids
granted -
US 11384337
Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 11384098
Pyrrolobenzodiazepine-antibody conjugates
granted -
US 11384076
Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors
granted -
US 11384065
Heterocyclic compound as CSF-1R inhibitor and use thereof
granted -
US 11384055
Glycolate oxidase inhibitors for the treatment of disease
granted -
US 11384062
Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
granted -
US 11382989
Engineered microbial population
granted -
US 11382979
Biodegradable lipids for the delivery of active agents
granted -
US 11382955
Long-acting VEGF inhibitors for intraocular neovascularization
granted -
US 11382932
Genetically engineered hematopoietic stem cells and uses thereof
granted -
US 11382976
Ultra-stable protein ionic liquids
granted -
US 11382929
Compositions and methods to treat disease
granted -
US 11382918
Methods for treating Huntington's Disease
granted -
US 11382899
Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery
granted -
US 11382885
Compositions for treating fungal and bacterial biofilms and methods of using the same
granted -
US 11382897
Therapeutic combination for treatment of cerebellar ataxia
granted -
US 11382880
Method for improving digestive health
granted -
US 11385233
Methods of depleting malignant T-cells
granted -
US 11384355
Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin
granted -
US 11384350
Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing
granted -
US 11384335
Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)
granted -
US 11384154
Targeted chimeric proteins and uses thereof
granted -
US 11384153
Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof
granted -
US 11384139
Antibody targeting cell surface deposited complement protein C3d and use thereof
granted -
US 11382981
Exon skipping oligomer conjugates for muscular dystrophy
granted -
US 11382922
Aqueous oral pharmaceutical suspension compositions
granted -
US 11382890
Prevention of rosacea inflammation
granted -
CA 3207179
METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE
granted -
US 11390687
Bispecific antibodies against plasma kallikrein and Factor XII
granted -
US 11390861
CRISPR/cas-related methods and compositions for treating herpes simplex virus
granted -
US 11389517
Peptide conjugated particles
granted -
US 11389566
Method and composition for treating inflammatory bowel disease
granted -
US 11389490
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11389481
Allogeneic cell therapy of B cell malignancies using genetically engineered T cells targeting CD19
granted -
US 11390921
Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
granted -
US 11390884
Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
granted -
US 11390848
Materials and methods for modifying the activity of T cells
granted -
US 11390683
Anti-mesothelin polypeptides and proteins
granted -
US 11390667
Compositions and methods for the treatment of neuromyelitis optica
granted -
US 11390631
Benzodiazepine derivatives as RSV inhibitors
granted -
US 11389663
Laser assisted wound healing protocol and system
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.